Holen Sie sich die Stockscreener-App
765.95
0.40%
-3.05
Vorhandelsmarkt:
766.07
0.12
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management - GlobeNewswire Inc.
Eli Lilly Age Bias Suit Sets 7th Cir. Collective-Action Test - Bloomberg Law News
Lilly Downplaying Obesity Drug Side Effects, Indiana Lawsuits Claim - InkFreeNews.com
Wisconsin offering up to $100M in development incentives to Eli Lilly's Kenosha County project - WPR
$100 million in state tax credits announced for Eli Lilly development in Kenosha County (Copy) - Wisconsin State Journal
Evers announces $100 million tax credits deal with Eli Lilly for Kenosha County development - Milwaukee Journal Sentinel
Lilly’s Kisunla Demonstrates Growing Benefit in Treating Early Alzheimer’s Disease - PharmTech
Eli Lilly eligible for up to $100M in tax breaks - The Business Journals
Eli Lilly secures up to $100M in tax credits for $4B Wisconsin expansion - Channel 3000
Amgen, Lilly Survive Bid to Dismiss Claims in Drug Discount Suit - Bloomberg Law News
Eli Lilly (LLY) Partners with LTZ to Develop Myeloid Engager Therapies - Insider Monkey
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly (NVO) - Seeking Alpha
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects - dailyjournal.net
Eli Lilly Reverses Early Weakness, Closes Near Day's High After Key Trading Signal - Benzinga
Eli Lilly opens tech, innovation centre in Hyd with plans to hire 1,500 in 2-3 yrs - Times of India
Indiana lawsuits accuse Lilly of downplaying obesity drug side effects - Inside INdiana Business
More than two dozen Indiana patients file lawsuits against Lilly over side effects of obesity drugs - The Indiana Lawyer
Eli Lilly Stock (LLY) Rises on Reports Medicare May Cover Weight-Loss Drugs - TipRanks
Eli Lilly stock rises on Medicare weight-loss drug coverage potential - Investing.com Canada
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings? - sharewise.com
Eli Lilly and Company (LLY) Slid Despite Strong Top-Line Growth - Insider Monkey
Lilly expands India presence with inauguration of Hyderabad site to accelerate global digital innovation - BioSpectrum India
Lilly’s Push to $1 Trillion Derailed by Trade Risks and Obesity Drug Speedbumps - Bloomberg.com
Why Novo Nordisk Outshines Eli Lilly as a Value Play in the GLP-1 Space - AInvest
Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside (NVO) - Seeking Alpha
Here’s Why Eli Lilly And Novo Nordisk Stocks Are Rallying Today - Stocktwits
The latest research on Eli Lilly and Co's Alzheimer's drug: Early use of donanemab can reduce the risk of disease progression. - 富途牛牛
The GLP-1 Gold Rush: Assessing the Financial Implications of Expanded Medicaid and Medicare Coverage for Eli Lilly and Novo Nordisk - AInvest
Why Eli Lilly Stock Topped the Market Today - The Motley Fool
Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed - Yahoo.co
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail
Lilly, Novo rally after report of Medicare weight loss coverage - TipRanks
U.S. Medicare plans to cover Eli Lilly and Co and Novo-Nordisk A/S GLP-1 weight loss drugs, with a pilot program set to begin in 2026. - 富途牛牛
Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings Projections - TipRanks
Eli Lilly price breaches upward correctional trend lineForecast today01-08-2025 - Economies.com
Eli Lilly: The Worst May Be Already Over (Earnings Preview) (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Stock Rises on Medicare Weight Loss Drug Coverage Plan - GuruFocus
Exxon Mobil, Eli Lilly, Moderna - TradingView
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial - PharmExec
Eli Lilly (LLY) Bulls Prepare for Multiyear Upside - TipRanks
Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing - MarketWatch
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer - Insider Monkey
Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results - simplywall.st
Trial Finds Eli Lilly’s (LLY) Diabetes Drug Mounjaro Has Heart Health Benefits - TipRanks
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Lilly’s Mounjaro as Effective on Heart Risks as Older Drug - Bloomberg.com
What Makes Eli Lilly and Company (LLY) a Lucrative Investment? - Insider Monkey
Lilly stock falls as Mounjaro fails to show superiority over Trulicity - Yahoo Finance
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study - Investing.com
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study By Investing.com - Investing.com India
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment - statnews.com
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):